1391063-17-4

Kinase inhibitors, such as?bosutinib,?are useful cancer drugs but their target specificity is not fully understood. 4-[(3,5-Dichloro-4-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile has been employed as a clinical kinase inhibitor bosutinib to elucidate the recognition mechanism between the ATP-binding site and the compound.

PF-06651481-00 is an isomer of orally available dual Src/Abl kinase inhibitor Bosutinib.